Gravar-mail: ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with (18)F-FDG PET and Correlation with Genotype and GLUT4 Expression